Payment overview · 2025
General Payments
$398.46
21 reported records · 12 companies
Healthcare provider profile · identity verified
Jerry David Phillips, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BAINBRIDGE, GA · NPI 1134133523
Verified facts
What the public records show
CMS Open Payments records show Jerry David Phillips, M.D. received $398.46 in general payments during 2025 across 21 reported records.
Novo Nordisk Inc accounted for 16.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Shingrix by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $64.84 | 16.3% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $63.82 | 16.0% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $62.48 | 15.7% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $47.21 | 11.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.03 | 8.5% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $22.31 | 5.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.10 | 5.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.38 | 4.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.81 | 4.5% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $17.55 | 4.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.98 | 3.5% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.95 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $398.46 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $63.82 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $63.82 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $62.48 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $47.21 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.03 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $34.03 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $22.31 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.31 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.09 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.09 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $21.10 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.10 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.10 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.38 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.81 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $17.55 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.98 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.95 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $13.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 68 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 67 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
68 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
68 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
23 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
36 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
131 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
67 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
147 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 528 | 111 |
| Alprazolam | Alprazolam | 505 | 77 |
| Levothyroxine Sodium | Levothyroxine Sodium | 462 | 80 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 418 | 62 |
| Meloxicam | Meloxicam | 385 | 79 |
| Gabapentin | Gabapentin | 384 | 80 |
| Amlodipine Besylate | Amlodipine Besylate | 362 | 76 |
| Hydrochlorothiazide | Hydrochlorothiazide | 339 | 80 |
| Sertraline Hcl | Sertraline Hcl | 299 | 50 |
| Omeprazole | Omeprazole | 292 | 64 |
| Tramadol Hcl | Tramadol Hcl | 284 | 63 |
| Furosemide | Furosemide | 278 | 59 |
| Zolpidem Tartrate | Zolpidem Tartrate | 277 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 269 | 58 |
| Potassium Chloride | Potassium Chloride | 238 | 56 |
| Lisinopril | Lisinopril | 226 | 60 |
| Losartan Potassium | Losartan Potassium | 218 | 52 |
| Tizanidine Hcl | Tizanidine Hcl | 210 | 41 |
| Ondansetron Odt | Ondansetron | 207 | 38 |
| Metformin Hcl | Metformin Hcl | 206 | 46 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 192 | 25 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 190 | 47 |
| Celecoxib | Celecoxib | 183 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 178 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 177 | 48 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 171 | 96 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 159 | 48 |
| Eliquis | Apixaban | 147 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 139 | 27 |
| Azithromycin | Azithromycin | 134 | 104 |
| Montelukast Sodium | Montelukast Sodium | 133 | 24 |
| Simvastatin | Simvastatin | 133 | 28 |
| Jardiance | Empagliflozin | 131 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 130 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 128 | 32 |
| Carvedilol | Carvedilol | 126 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 125 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 125 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 124 | 35 |
| Donepezil Hcl | Donepezil Hcl | 122 | 21 |
| Methylprednisolone | Methylprednisolone | 115 | 66 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 111 | 77 |
| Trazodone Hcl | Trazodone Hcl | 107 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 105 | 41 |
| Glimepiride | Glimepiride | 98 | 20 |
| Cephalexin | Cephalexin | 97 | 49 |
| Oxycodone Hcl | Oxycodone Hcl | 97 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 96 | 19 |
| Allopurinol | Allopurinol | 91 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 89 | 62 |
| Promethazine Hcl | Promethazine Hcl | 85 | 24 |
| Levofloxacin | Levofloxacin | 84 | 68 |
| Pregabalin | Pregabalin | 81 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 80 | 27 |
| Nifedipine Er | Nifedipine | 76 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 75 | 11 |
| Temazepam | Temazepam | 69 | 13 |
| Farxiga | Dapagliflozin Propanediol | 68 | suppressed |
| Linzess | Linaclotide | 68 | 18 |
| Ozempic | Semaglutide | 67 | 14 |
| Ibuprofen | Ibuprofen | 66 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 64 | 11 |
| Mirtazapine | Mirtazapine | 64 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 64 | 11 |
| Prednisone | Prednisone | 64 | 25 |
| Fluconazole | Fluconazole | 63 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 63 | 11 |
| Famotidine | Famotidine | 60 | 11 |
| Colchicine | Colchicine | 57 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 56 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 55 | 13 |
| Metformin Hcl Er | Metformin Hcl | 54 | 15 |
| Lorazepam | Lorazepam | 53 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 12 |
| Meclizine Hcl | Meclizine Hcl | 51 | 19 |
| Myrbetriq | Mirabegron | 50 | suppressed |
| Aripiprazole | Aripiprazole | 48 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 46 | suppressed |
| Estradiol | Estradiol | 45 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 44 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 42 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | suppressed |
| Memantine Hcl | Memantine Hcl | 40 | suppressed |
| Atenolol | Atenolol | 39 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 39 | 19 |
| Clonazepam | Clonazepam | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Hydrocortisone | Hydrocortisone | 37 | 20 |
| Lactulose | Lactulose | 37 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 37 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 37 | suppressed |
| Olanzapine | Olanzapine | 36 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 36 | 27 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | suppressed |
| Spironolactone | Spironolactone | 35 | suppressed |
| Ketoconazole | Ketoconazole | 34 | 15 |
| Bumetanide | Bumetanide | 32 | suppressed |
| Glipizide Er | Glipizide | 32 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 22 |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Entresto | Sacubitril/Valsartan | 29 | suppressed |
| Methocarbamol | Methocarbamol | 29 | suppressed |
| Risperidone | Risperidone | 29 | suppressed |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Diazepam | Diazepam | 28 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Ramipril | Ramipril | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 26 | 22 |
| Dexamethasone | Dexamethasone | 26 | 25 |
| Fentanyl | Fentanyl | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 24 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 24 | 19 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 23 | 23 |
| Benztropine Mesylate | Benztropine Mesylate | 23 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 23 | suppressed |
| Nystatin | Nystatin | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 20 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 18 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Cefdinir | Cefdinir | 16 | 13 |
| Dilt-Xr | Diltiazem Hcl | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 14 | suppressed |
| Levemir | Insulin Detemir | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 12 |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Alprazolam Odt | Alprazolam | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 12 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $398.46 · 21 records | Novo Nordisk Inc | ABRYSVO, CAPLYTA, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, FARXIGA, GARDASIL 9, MOUNJARO, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, Wegovy, XIFAXAN, ZEPBOUND, ZORYVE | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error